Novel  ||| S:0 E:6 ||| NNP
Once-Daily  ||| S:6 E:17 ||| NNP
Extended-Release  ||| S:17 E:34 ||| NNP
Tacrolimus  ||| S:34 E:45 ||| NNP
Versus  ||| S:45 E:52 ||| NNP
Twice-Daily  ||| S:52 E:64 ||| NNP
Tacrolimus  ||| S:64 E:75 ||| NNP
in  ||| S:75 E:78 ||| IN
De  ||| S:78 E:81 ||| NNP
Novo  ||| S:81 E:86 ||| NNP
Kidney  ||| S:86 E:93 ||| NNP
Transplant  ||| S:93 E:104 ||| NNP
Recipients ||| S:104 E:114 ||| NNP
:  ||| S:114 E:116 ||| :
Two-Year  ||| S:116 E:125 ||| JJ
Results  ||| S:125 E:133 ||| NNS
of  ||| S:133 E:136 ||| IN
Phase  ||| S:136 E:142 ||| NNP
3 ||| S:142 E:143 ||| CD
,  ||| S:143 E:145 ||| ,
Double-Blind ||| S:145 E:157 ||| NNP
,  ||| S:157 E:159 ||| ,
Randomized  ||| S:159 E:170 ||| NNP
Trial  ||| S:170 E:176 ||| NNP
1-year  ||| S:176 E:183 ||| NNP
data  ||| S:183 E:188 ||| NNS
from  ||| S:188 E:193 ||| IN
this  ||| S:193 E:198 ||| DT
trial  ||| S:198 E:204 ||| NN
showed  ||| S:204 E:211 ||| VBD
the  ||| S:211 E:215 ||| DT
noninferiority  ||| S:215 E:230 ||| NN
of  ||| S:230 E:233 ||| IN
a  ||| S:233 E:235 ||| DT
novel  ||| S:235 E:241 ||| NN
once-daily  ||| S:241 E:252 ||| JJ
extended-release  ||| S:252 E:269 ||| JJ
tacrolimus  ||| S:269 E:280 ||| NNS
( ||| S:280 E:281 ||| -LRB-
LCPT ||| S:281 E:285 ||| NNP
;  ||| S:285 E:287 ||| :
Envarsus  ||| S:287 E:296 ||| NNP
XR ||| S:296 E:298 ||| NNP
)  ||| S:298 E:300 ||| -RRB-
to  ||| S:300 E:303 ||| TO
immediate-release  ||| S:303 E:321 ||| JJ
tacrolimus  ||| S:321 E:332 ||| NNS
( ||| S:332 E:333 ||| -LRB-
IR-Tac ||| S:333 E:339 ||| NNP
)  ||| S:339 E:341 ||| -RRB-
twice  ||| S:341 E:347 ||| RB
daily  ||| S:347 E:353 ||| JJ
after  ||| S:353 E:359 ||| IN
kidney  ||| S:359 E:366 ||| NN
transplantation ||| S:366 E:381 ||| NN
.  ||| S:381 E:383 ||| .
Final  ||| S:383 E:389 ||| JJ
24-month  ||| S:389 E:398 ||| JJ
analysis  ||| S:398 E:407 ||| NN
of  ||| S:407 E:410 ||| IN
a  ||| S:410 E:412 ||| DT
2-armed ||| S:412 E:419 ||| NNP
,  ||| S:419 E:421 ||| ,
parallel-group ||| S:421 E:435 ||| NNP
,  ||| S:435 E:437 ||| ,
randomized ||| S:437 E:447 ||| NN
,  ||| S:447 E:449 ||| ,
double-blind ||| S:449 E:461 ||| NNP
,  ||| S:461 E:463 ||| ,
double-dummy ||| S:463 E:475 ||| NNP
,  ||| S:475 E:477 ||| ,
multicenter ||| S:477 E:488 ||| NN
,  ||| S:488 E:490 ||| ,
phase  ||| S:490 E:496 ||| NN
3  ||| S:496 E:498 ||| CD
trial.  ||| S:498 E:505 ||| CD
543  ||| S:505 E:509 ||| CD
de  ||| S:509 E:512 ||| IN
novo  ||| S:512 E:517 ||| JJ
kidney  ||| S:517 E:524 ||| NN
recipients  ||| S:524 E:535 ||| NNS
randomly  ||| S:535 E:544 ||| RB
assigned  ||| S:544 E:553 ||| VBN
to  ||| S:553 E:556 ||| TO
LCPT  ||| S:556 E:561 ||| NNP
( ||| S:561 E:562 ||| -LRB-
n=268 ||| S:562 E:567 ||| NNP
)  ||| S:567 E:569 ||| -RRB-
or  ||| S:569 E:572 ||| CC
IR-Tac  ||| S:572 E:579 ||| NNP
( ||| S:579 E:580 ||| -LRB-
n=275 ||| S:580 E:585 ||| NNP
) ||| S:585 E:586 ||| -RRB-
;  ||| S:586 E:588 ||| :
507  ||| S:588 E:592 ||| CD
( ||| S:592 E:593 ||| -LRB-
93.4 ||| S:593 E:597 ||| NNP
% ||| S:597 E:598 ||| NN
)  ||| S:598 E:600 ||| -RRB-
completed  ||| S:600 E:610 ||| VBD
the  ||| S:610 E:614 ||| DT
24-month  ||| S:614 E:623 ||| JJ
study ||| S:623 E:628 ||| NN
.  ||| S:628 E:630 ||| .
LCPT  ||| S:630 E:635 ||| NNP
tablets  ||| S:635 E:643 ||| NNS
once  ||| S:643 E:648 ||| RB
daily  ||| S:648 E:654 ||| JJ
at  ||| S:654 E:657 ||| IN
0.17  ||| S:657 E:662 ||| CD
mg ||| S:662 E:664 ||| CD
/ ||| S:664 E:665 ||| CD
kg ||| S:665 E:667 ||| CD
/ ||| S:667 E:668 ||| CD
d  ||| S:668 E:670 ||| NNS
or  ||| S:670 E:673 ||| CC
IR-Tac  ||| S:673 E:680 ||| JJ
twice  ||| S:680 E:686 ||| RB
daily  ||| S:686 E:692 ||| JJ
at  ||| S:692 E:695 ||| IN
0.1  ||| S:695 E:699 ||| CD
mg ||| S:699 E:701 ||| CD
/ ||| S:701 E:702 ||| CD
kg ||| S:702 E:704 ||| CD
/ ||| S:704 E:705 ||| CD
d ||| S:705 E:706 ||| SYM
;  ||| S:706 E:708 ||| :
subsequent  ||| S:708 E:719 ||| JJ
doses  ||| S:719 E:725 ||| NNS
were  ||| S:725 E:730 ||| VBD
adjusted  ||| S:730 E:739 ||| VBN
to  ||| S:739 E:742 ||| TO
maintain  ||| S:742 E:751 ||| VB
target  ||| S:751 E:758 ||| NN
trough  ||| S:758 E:765 ||| NN
ranges  ||| S:765 E:772 ||| NNS
( ||| S:772 E:773 ||| -LRB-
first  ||| S:773 E:779 ||| JJ
30  ||| S:779 E:782 ||| CD
days ||| S:782 E:786 ||| NNS
,  ||| S:786 E:788 ||| ,
6-11  ||| S:788 E:793 ||| FW
ng ||| S:793 E:795 ||| FW
/ ||| S:795 E:796 ||| FW
mL ||| S:796 E:798 ||| FW
;  ||| S:798 E:800 ||| :
thereafter ||| S:800 E:810 ||| RB
,  ||| S:810 E:812 ||| ,
4-11  ||| S:812 E:817 ||| FW
ng ||| S:817 E:819 ||| FW
/ ||| S:819 E:820 ||| FW
mL ||| S:820 E:822 ||| FW
) ||| S:822 E:823 ||| -RRB-
.  ||| S:823 E:825 ||| .
The  ||| S:825 E:829 ||| DT
intervention  ||| S:829 E:842 ||| NN
was  ||| S:842 E:846 ||| VBD
24  ||| S:846 E:849 ||| CD
months ||| S:849 E:855 ||| NNS
;  ||| S:855 E:857 ||| :
the  ||| S:857 E:861 ||| DT
study  ||| S:861 E:867 ||| NN
was  ||| S:867 E:871 ||| VBD
double  ||| S:871 E:878 ||| JJ
blinded  ||| S:878 E:886 ||| NN
for  ||| S:886 E:890 ||| IN
the  ||| S:890 E:894 ||| DT
entirety ||| S:894 E:902 ||| NN
.  ||| S:902 E:904 ||| .
Treatment  ||| S:904 E:914 ||| NN
failure  ||| S:914 E:922 ||| NN
( ||| S:922 E:923 ||| -LRB-
death ||| S:923 E:928 ||| NN
,  ||| S:928 E:930 ||| ,
transplant  ||| S:930 E:941 ||| JJ
failure ||| S:941 E:948 ||| NN
,  ||| S:948 E:950 ||| ,
biopsy-proven  ||| S:950 E:964 ||| JJ
acute  ||| S:964 E:970 ||| JJ
rejection ||| S:970 E:979 ||| NN
,  ||| S:979 E:981 ||| ,
or  ||| S:981 E:984 ||| CC
loss  ||| S:984 E:989 ||| NN
to  ||| S:989 E:992 ||| TO
follow  ||| S:992 E:999 ||| VB
up ||| S:999 E:1001 ||| RP
)  ||| S:1001 E:1003 ||| -RRB-
within  ||| S:1003 E:1010 ||| IN
24  ||| S:1010 E:1013 ||| CD
months ||| S:1013 E:1019 ||| NNS
.  ||| S:1019 E:1021 ||| .
Safety  ||| S:1021 E:1028 ||| NN
end  ||| S:1028 E:1032 ||| NN
points  ||| S:1032 E:1039 ||| NNS
included  ||| S:1039 E:1048 ||| VBD
adverse  ||| S:1048 E:1056 ||| JJ
events ||| S:1056 E:1062 ||| NNS
,  ||| S:1062 E:1064 ||| ,
serious  ||| S:1064 E:1072 ||| JJ
adverse  ||| S:1072 E:1080 ||| JJ
events ||| S:1080 E:1086 ||| NNS
,  ||| S:1086 E:1088 ||| ,
new-onset  ||| S:1088 E:1098 ||| JJ
diabetes ||| S:1098 E:1106 ||| NN
,  ||| S:1106 E:1108 ||| ,
kidney  ||| S:1108 E:1115 ||| NN
function ||| S:1115 E:1123 ||| NN
,  ||| S:1123 E:1125 ||| ,
opportunistic  ||| S:1125 E:1139 ||| JJ
infections ||| S:1139 E:1149 ||| NNS
,  ||| S:1149 E:1151 ||| ,
and  ||| S:1151 E:1155 ||| CC
malignancies ||| S:1155 E:1167 ||| NN
.  ||| S:1167 E:1169 ||| .
Pharmacokinetic  ||| S:1169 E:1185 ||| JJ
measures  ||| S:1185 E:1194 ||| NNS
included  ||| S:1194 E:1203 ||| VBD
total  ||| S:1203 E:1209 ||| JJ
daily  ||| S:1209 E:1215 ||| JJ
dose  ||| S:1215 E:1220 ||| NN
( ||| S:1220 E:1221 ||| -LRB-
TDD ||| S:1221 E:1224 ||| NNP
)  ||| S:1224 E:1226 ||| -RRB-
of  ||| S:1226 E:1229 ||| IN
study  ||| S:1229 E:1235 ||| NN
drugs  ||| S:1235 E:1241 ||| NNS
and  ||| S:1241 E:1245 ||| CC
tacrolimus  ||| S:1245 E:1256 ||| JJ
trough  ||| S:1256 E:1263 ||| NN
levels.  ||| S:1263 E:1271 ||| CD
24-month  ||| S:1271 E:1280 ||| JJ
treatment  ||| S:1280 E:1290 ||| NN
failure  ||| S:1290 E:1298 ||| NN
was  ||| S:1298 E:1302 ||| VBD
LCPT ||| S:1302 E:1306 ||| NNP
,  ||| S:1306 E:1308 ||| ,
23.1 ||| S:1308 E:1312 ||| CD
% ||| S:1312 E:1313 ||| NN
;  ||| S:1313 E:1315 ||| :
IR-Tac ||| S:1315 E:1321 ||| NNP
,  ||| S:1321 E:1323 ||| ,
27.3 ||| S:1323 E:1327 ||| CD
%  ||| S:1327 E:1329 ||| NN
( ||| S:1329 E:1330 ||| -LRB-
treatment  ||| S:1330 E:1340 ||| NN
difference ||| S:1340 E:1350 ||| NN
,  ||| S:1350 E:1352 ||| ,
-4.14 ||| S:1352 E:1357 ||| CD
%  ||| S:1357 E:1359 ||| NN
[ ||| S:1359 E:1360 ||| -LRB-
95 ||| S:1360 E:1362 ||| CD
%  ||| S:1362 E:1364 ||| NN
CI ||| S:1364 E:1366 ||| NNP
,  ||| S:1366 E:1368 ||| ,
-11.38 ||| S:1368 E:1374 ||| CD
%  ||| S:1374 E:1376 ||| NN
to  ||| S:1376 E:1379 ||| TO
+3.17 ||| S:1379 E:1384 ||| CD
% ||| S:1384 E:1385 ||| NN
] ||| S:1385 E:1386 ||| -RRB-
,  ||| S:1386 E:1388 ||| ,
well  ||| S:1388 E:1393 ||| RB
below  ||| S:1393 E:1399 ||| IN
the  ||| S:1399 E:1403 ||| DT
+10 ||| S:1403 E:1406 ||| JJ
%  ||| S:1406 E:1408 ||| NN
noninferiority  ||| S:1408 E:1423 ||| NNS
criterion  ||| S:1423 E:1433 ||| VBP
defined  ||| S:1433 E:1441 ||| VBN
for  ||| S:1441 E:1445 ||| IN
the  ||| S:1445 E:1449 ||| DT
primary  ||| S:1449 E:1457 ||| JJ
12-month  ||| S:1457 E:1466 ||| JJ
end  ||| S:1466 E:1470 ||| NN
point ||| S:1470 E:1475 ||| NN
) ||| S:1475 E:1476 ||| -RRB-
.  ||| S:1476 E:1478 ||| .
Subgroup  ||| S:1478 E:1487 ||| JJ
analyses  ||| S:1487 E:1496 ||| NNS
showed  ||| S:1496 E:1503 ||| VBD
fewer  ||| S:1503 E:1509 ||| JJR
treatment  ||| S:1509 E:1519 ||| NN
failures  ||| S:1519 E:1528 ||| NNS
for  ||| S:1528 E:1532 ||| IN
LCPT  ||| S:1532 E:1537 ||| NNP
versus  ||| S:1537 E:1544 ||| CC
IR-Tac  ||| S:1544 E:1551 ||| JJ
among  ||| S:1551 E:1557 ||| IN
black ||| S:1557 E:1562 ||| JJ
,  ||| S:1562 E:1564 ||| ,
older ||| S:1564 E:1569 ||| JJR
,  ||| S:1569 E:1571 ||| ,
and  ||| S:1571 E:1575 ||| CC
female  ||| S:1575 E:1582 ||| JJ
recipients ||| S:1582 E:1592 ||| NNS
.  ||| S:1592 E:1594 ||| .
Safety  ||| S:1594 E:1601 ||| NNP
was  ||| S:1601 E:1605 ||| VBD
similar  ||| S:1605 E:1613 ||| JJ
between  ||| S:1613 E:1621 ||| IN
groups ||| S:1621 E:1627 ||| NNS
.  ||| S:1627 E:1629 ||| .
From  ||| S:1629 E:1634 ||| IN
month  ||| S:1634 E:1640 ||| NN
1 ||| S:1640 E:1641 ||| CD
,  ||| S:1641 E:1643 ||| ,
TDD  ||| S:1643 E:1647 ||| NNP
was  ||| S:1647 E:1651 ||| VBD
lower  ||| S:1651 E:1657 ||| JJR
for  ||| S:1657 E:1661 ||| IN
LCPT ||| S:1661 E:1665 ||| NNP
;  ||| S:1665 E:1667 ||| :
the  ||| S:1667 E:1671 ||| DT
difference  ||| S:1671 E:1682 ||| NN
increased  ||| S:1682 E:1692 ||| VBN
over  ||| S:1692 E:1697 ||| IN
time ||| S:1697 E:1701 ||| NN
.  ||| S:1701 E:1703 ||| .
At  ||| S:1703 E:1706 ||| IN
month  ||| S:1706 E:1712 ||| NN
24 ||| S:1712 E:1714 ||| CD
,  ||| S:1714 E:1716 ||| ,
mean  ||| S:1716 E:1721 ||| JJ
TDD  ||| S:1721 E:1725 ||| NN
for  ||| S:1725 E:1729 ||| IN
LCPT  ||| S:1729 E:1734 ||| NNP
was  ||| S:1734 E:1738 ||| VBD
24 ||| S:1738 E:1740 ||| CD
%  ||| S:1740 E:1742 ||| NN
lower  ||| S:1742 E:1748 ||| JJR
than  ||| S:1748 E:1753 ||| IN
for  ||| S:1753 E:1757 ||| IN
the  ||| S:1757 E:1761 ||| DT
IR-Tac  ||| S:1761 E:1768 ||| JJ
group  ||| S:1768 E:1774 ||| NN
( ||| S:1774 E:1775 ||| -LRB-
P  ||| S:1775 E:1776 ||| NNP
< ||| S:1776 E:1777 ||| SYM
0.001 ||| S:1777 E:1782 ||| NNP
) ||| S:1782 E:1783 ||| -RRB-
,  ||| S:1783 E:1785 ||| ,
but  ||| S:1785 E:1789 ||| CC
troughs  ||| S:1789 E:1797 ||| NNS
were  ||| S:1797 E:1802 ||| VBD
similar  ||| S:1802 E:1810 ||| JJ
( ||| S:1810 E:1811 ||| -LRB-
means  ||| S:1811 E:1817 ||| NNS
at  ||| S:1817 E:1820 ||| IN
24  ||| S:1820 E:1823 ||| CD
months ||| S:1823 E:1829 ||| NNS
:  ||| S:1829 E:1831 ||| :
LCPT ||| S:1831 E:1835 ||| NNP
,  ||| S:1835 E:1837 ||| ,
5.47  ||| S:1837 E:1842 ||| CD
±  ||| S:1842 E:1844 ||| CD
0.17  ||| S:1844 E:1849 ||| CD
ng ||| S:1849 E:1851 ||| CD
/ ||| S:1851 E:1852 ||| CD
mL ||| S:1852 E:1854 ||| NN
;  ||| S:1854 E:1856 ||| :
IR-Tac ||| S:1856 E:1862 ||| NNP
,  ||| S:1862 E:1864 ||| ,
5.8  ||| S:1864 E:1868 ||| CD
±  ||| S:1868 E:1870 ||| CD
0.30  ||| S:1870 E:1875 ||| CD
ng ||| S:1875 E:1877 ||| CD
/ ||| S:1877 E:1878 ||| CD
mL ||| S:1878 E:1880 ||| NN
;  ||| S:1880 E:1882 ||| :
P=0.4 ||| S:1882 E:1887 ||| CD
) ||| S:1887 E:1888 ||| -RRB-
.  ||| S:1888 E:1890 ||| .
Trial  ||| S:1890 E:1896 ||| NN
participant  ||| S:1896 E:1908 ||| NN
eligibility  ||| S:1908 E:1920 ||| NN
criteria  ||| S:1920 E:1929 ||| NNS
may  ||| S:1929 E:1933 ||| MD
limit  ||| S:1933 E:1939 ||| VB
the  ||| S:1939 E:1943 ||| DT
generalizability  ||| S:1943 E:1960 ||| NN
of  ||| S:1960 E:1963 ||| IN
results  ||| S:1963 E:1971 ||| NNS
to  ||| S:1971 E:1974 ||| TO
the  ||| S:1974 E:1978 ||| DT
global  ||| S:1978 E:1985 ||| JJ
population  ||| S:1985 E:1996 ||| NN
of  ||| S:1996 E:1999 ||| IN
de  ||| S:1999 E:2002 ||| FW
novo  ||| S:2002 E:2007 ||| FW
kidney  ||| S:2007 E:2014 ||| FW
transplant  ||| S:2014 E:2025 ||| FW
recipients ||| S:2025 E:2035 ||| FW
.  ||| S:2035 E:2037 ||| .
Results  ||| S:2037 E:2045 ||| NNS
suggest  ||| S:2045 E:2053 ||| VBP
that  ||| S:2053 E:2058 ||| IN
once-daily  ||| S:2058 E:2069 ||| JJ
LCPT  ||| S:2069 E:2074 ||| NN
in  ||| S:2074 E:2077 ||| IN
de  ||| S:2077 E:2080 ||| FW
novo  ||| S:2080 E:2085 ||| FW
kidney  ||| S:2085 E:2092 ||| FW
transplantation  ||| S:2092 E:2108 ||| FW
has  ||| S:2108 E:2112 ||| VBZ
comparable  ||| S:2112 E:2123 ||| JJ
efficacy  ||| S:2123 E:2132 ||| NN
and  ||| S:2132 E:2136 ||| CC
safety  ||| S:2136 E:2143 ||| NN
profile  ||| S:2143 E:2151 ||| NN
to  ||| S:2151 E:2154 ||| TO
that  ||| S:2154 E:2159 ||| DT
of  ||| S:2159 E:2162 ||| IN
IR-Tac ||| S:2162 E:2168 ||| JJ
.  ||| S:2168 E:2170 ||| .
Lower  ||| S:2170 E:2176 ||| JJR
TDD  ||| S:2176 E:2180 ||| NNP
reflects  ||| S:2180 E:2189 ||| VBZ
LCPT ||| S:2189 E:2193 ||| NNP
's  ||| S:2193 E:2196 ||| POS
improved  ||| S:2196 E:2205 ||| JJ
bioavailability  ||| S:2205 E:2221 ||| NN
and  ||| S:2221 E:2225 ||| CC
absorption ||| S:2225 E:2235 ||| NN
.  ||| S:2235 E:2237 ||| .
